Nektar Therapeutics (NKTR) Common Equity (2010 - 2026)

Nektar Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $576.2 million for Q1 2026.

• In Q1 2026, Common Equity rose 4094.32% year-over-year to $576.2 million; the TTM figure through Mar 2026 stood at $576.2 million (up 4094.32% YoY), while the FY2025 annual figure was $89.8 million, up 47.9% from the prior year.
• Common Equity was $576.2 million for Q1 2026 at Nektar Therapeutics, up from $89.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $607.9 million in Q1 2022 to a low of -$24.2 million in Q2 2025.
• Historically, Common Equity has averaged $213.5 million across 5 years, with a median of $131.0 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Common Equity plunged 130.38% in 2025, then soared 4094.32% in 2026.
• A 5-year view of Common Equity shows it stood at $366.6 million in 2022, then sank by 64.27% to $131.0 million in 2023, then plunged by 53.63% to $60.7 million in 2024, then jumped by 47.9% to $89.8 million in 2025, then jumped by 541.44% to $576.2 million in 2026.
• The last three Common Equity figures came in at $576.2 million (Q1 2026), $89.8 million (Q4 2025), and $85.1 million (Q3 2025), per Business Quant data.